FDA Approves JAZZ's Ziihera for First-Line HER2+ GEA — Full Analysis

APPROVED August 25, 2026: The FDA approved Ziihera for first-line HER2+ GEA on the PDUFA date. Read the breaking coverage →

Jazz Pharmaceuticals closed Tuesday at $255.97. That prices the company at $16.1 billion in market cap. Ziihera, which won FDA approval for first-line GEA on August 25, generated $13.3 million in Q1 2026 sales. That is 1.3% of quarterly revenue. The market was not waiting on this PDUFA. Neither should you, if you are trading the stock. If you are building a position in the franchise, the data is better than the price suggests.

The August 25 PDUFA is not what the headline writers think it is. Ziihera (zanidatamab-hrii) already has accelerated approval for previously treated HER2-positive biliary tract cancer, granted in November 2023. That indication generated $24.8 million in full-year 2025 sales and $13.3 million in Q1 2026. The August 25 sBLA is for a completely different indication: first-line HER2-positive gastroesophageal adenocarcinoma (GEA), based on the Phase 3 HERIZON-GEA-01 trial. This is an sBLA for label expansion, not a confirmatory conversion of the BTC accelerated approval. The distinction matters because GEA is a 10x larger market than BTC.

The Phase 3 data is genuinely strong

HERIZON-GEA-01 (NCT05152147) is a global, open-label, randomized Phase 3 trial enrolling 914 patients with previously untreated HER2-positive locally advanced or metastatic GEA, regardless of PD-L1 status. Patients were randomized 1:1:1 to zanidatamab plus tislelizumab plus chemotherapy, zanidatamab plus chemotherapy, or trastuzumab plus chemotherapy. The dual primary endpoints were progression-free survival by blinded independent central review and overall survival.

The results, published in the New England Journal of Medicine, are a clean Phase 3 win over the incumbent standard of care in front-line GEA:

• Median PFS: 12.4 months for both zanidatamab arms vs 8.1 months for trastuzumab plus chemotherapy. Hazard ratio 0.65 (95% CI 0.52-0.81, p<0.0001) for the doublet and 0.63 (95% CI 0.51-0.78, p<0.0001) for the triplet.
• Median OS: 26.4 months for the triplet vs 19.2 months for control. Hazard ratio 0.72 (95% CI 0.57-0.90, p=0.0043). The doublet showed a strong trend at 24.4 months (HR 0.80, p=0.0564 at interim), with a second OS analysis expected mid-2026.
• 24-month OS rate: 54.3% for the triplet, 50.3% for the doublet, 38.8% for control.

Trastuzumab plus chemotherapy has been the HER2-positive GEA standard since 2010. Zanidatamab is a bispecific antibody targeting two non-overlapping HER2 epitopes (ECD2 and ECD4), which enables cross-linking and enhanced receptor clustering compared to trastuzumab’s single-epitope binding. The mechanism translates: a 4.3-month PFS improvement and a 7.2-month OS improvement over the incumbent is not incremental. It is a potential practice change.

But this is a $16 billion sleep company

Jazz is Xyrem and Xywav. The sleep franchise drives the income statement. Q1 2026 total revenue was $1.07 billion. Xywav added 425 net new patients in the quarter with 18% YoY revenue growth. Ziihera’s $13.3 million in Q1 is a rounding error against the oxybate franchise.

Even in a bullish scenario, Ziihera’s GEA opportunity is modest relative to the parent. GEA has roughly 27,000 new US cases per year. HER2-positive prevalence runs 15-20% in GEA, so the addressable population is roughly 4,000-5,400 patients annually. At a $10,000 per month drug cost and 12 months of treatment, peak GEA revenue could reach $500-600 million. Add the BTC indication at maybe $50-75 million peak, and Ziihera is a $600-700 million franchise. Against $4.25-4.50 billion in 2026 total revenue guidance, that is 15% of revenue at peak, years away.

Compare this to Daiichi Sankyo’s ENHERTU platform, where a single ADC drives multi-billion-dollar franchise value at a pharma company with a comparable market cap. Ziihera is not ENHERTU. It is a bispecific antibody with a clean Phase 3 dataset in a niche indication, not a pipeline-in-a-product across five tumor types.

The BTC accelerated approval context

The existing BTC indication is worth understanding because it tells you something about the FDA’s comfort level with zanidatamab. The November 2023 accelerated approval was based on HERIZON-BTC-01, a single-arm Phase 2b trial in 80 previously treated HER2-positive BTC patients. The confirmed ORR was 41.3% (95% CI 30.4-52.8%) with a median duration of response of 14.9 months. In the IHC 3+ subgroup (62 patients), ORR was 51.6% and median OS was 18.1 months.

That is a respectable single-arm result in a brutal disease. Biliary tract cancer has a 5-year survival rate below 10% for advanced disease. But single-arm data is not randomized data, and the FDA’s accelerated approval pathway is under scrutiny. With the GEA sBLA now approved on August 25, the FDA has further validated the zanidatamab safety profile. The BTC accelerated approval, which still faces its own confirmatory milestone, benefits from this vote of confidence.

Risk factors: grade 3 diarrhea and competitive dynamics

The HERIZON-GEA-01 safety data has a real signal. Grade 3 or higher treatment-related adverse events occurred in 71.8% of the triplet arm, 59.0% of the doublet arm, and 59.6% of the control arm. Grade 3 diarrhea, hypokalemia, and anemia were the most common events exceeding 10% in the zanidatamab arms. HER2-targeted therapy was discontinued for related adverse events in 11.9% of triplet patients and 8.5% of doublet patients, compared to 2.3% in the trastuzumab arm. That discontinuation rate is 3-5x higher than the incumbent. In community oncology, where most GEA patients are treated, that kind of tolerability gap can slow adoption even with superior efficacy.

The competitive picture is also evolving. ENHERTU has shown activity in HER2-low GEA in the DESTINY-Gastric01 and DESTINY-Gastric02 trials, and Daiichi is pushing into earlier lines. If ENHERTU moves into first-line HER2-positive GEA, zanidatamab’s window as the new standard narrows. Zanidatamab’s advantage today is that it beat trastuzumab head-to-head in Phase 3, which ENHERTU has not yet done in first-line GEA. But ENHERTU’s ADC payload produces responses in HER2-low disease where zanidatamab’s bispecific mechanism has no demonstrated activity.

Verdict

The FDA approved Ziihera for first-line GEA on August 25, as expected. The Phase 3 data, published in NEJM, shows a 4.3-month PFS improvement and a 7.2-month OS improvement over the 2010 standard, with a clean primary endpoint win on PFS and a statistically significant OS benefit for the triplet. The FDA granted Priority Review, consistent with the strength of the submission package.

But JAZZ remains a Hold regardless. At $16.1 billion, the stock still trades on Xywav growth, Xyrem generic erosion timing, and the Zepzelca lung cancer franchise. Ziihera is optionality. The GEA label expansion is approved, and Ziihera’s peak sales contribution reaches maybe $600 million over 5 years. That adds 15% to revenue at maturity, discounted back 5 years at 10%, and it does not move a $16 billion stock.

The trade for investors who want exposure to the Ziihera data is not JAZZ. It is BeOne Medicines (the former BeiGene), which co-developed HERIZON-GEA-01 and contributes tislelizumab to the triplet regimen. BeOne trades at roughly $22 billion in market cap, smaller than Jazz but still a mid-cap pharma with a diversified oncology portfolio. For BeOne, the tislelizumab-plus-zanidatamab combination in first-line GEA is a meaningful pipeline asset with a potential $300-400 million peak contribution, given that tislelizumab is already approved in esophageal squamous cell carcinoma and NSCLC. The GEA approval is the first pairing of the two drugs in a validated regimen. That said, $22 billion is still large enough that a single label expansion moves the stock by low single digits, not 30%.

The broader pattern here is one biotech investors learn the hard way: Phase 3 data quality and stock-moving potential are inversely correlated at large-cap pharma. The best trial of the year can produce a 3% move because the drug is 1% of revenue. The same data at a $500 million micro-cap would double the stock. HERIZON-GEA-01 is a genuinely well-designed trial with a clean win over an entrenched standard of care. The investors who will profit from it are not the ones buying JAZZ on August 24. They are the ones who understood the data when it was presented at ASCO GI in January 2026, bought the pullback, and held through the PDUFA. For Jazz, this PDUFA is a pipeline diversification story in a sleep company with an oncology kicker. Sleep well.